Protagenic Therapeutics (PTIX)

Name: Protagenic Therapeutics (PTIX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Protagenic Therapeutics (PTIX)

Stock Card

$0.94

$0.03 (2.76%)

As on 28-Aug-2026 12:29EDT

Market cap

$1 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

3.3

Div. Yield

0 %

Protagenic Therapeutics (PTIX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.94 High: 0.94

52 Week Range

Low: 0.00 High: 4.55

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-5.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.6
Debt to Equity

-1.3
Book Value

$--
EPS

$-2.7
Face value

--
Shares outstanding

1,810,208

10 Years Aggregate

CFO

$-15.47 Mln

EBITDA

$-24.32 Mln

Net Profit

$-27.27 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Protagenic Therapeutics (PTIX)	-28.1	563.2	100.9	-76.0	-20.8	-35.5	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020
Protagenic Therapeutics (PTIX)	165.3	-50.2	-38.1	-71.1	31.9	-25.5
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Protagenic Therapeutics (PTIX)	0.9	1.5	0.0	-5.2	--	747.5	--	3.3
Arrowhead Pharmaceuticals (ARWR)	84.9	12,304.7	669.5	-320.0	-0.8	-71.1	--	26.4
Ascendis Pharma A/S - ADR	246.7	16,614.0	1,054.4	755.9	5.7	--	19.4	10.1
Cytokinetics Inc (CYTK)	72.3	10,682.6	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.2	13,400.0	2,435.9	860.6	31.0	43	17	7.3
Halozyme Therapeutics (HALO)	105.3	12,277.1	1,663.7	413.6	36.3	430	31.2	83.9
Krystal Biotech (KRYS)	350.5	10,258.4	440.5	241.5	33.4	18.7	42.2	7.3
Madrigal Pharmaceuticals (MDGL)	534.5	11,938.8	1,283.9	-325.1	-19.0	-57.7	--	22.9
Medpace Holdings (MEDP)	603.9	17,326.2	2,782.3	491.5	21.1	110.1	36.5	39.4
Praxis Precision MedicinesÂ Inc (PRAX)	348.4	10,496.2	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Protagenic Therapeutics (PTIX)

Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa... Barbara, California. Read more

Co-Founder & Executive Chairman of the Board

Dr. Garo H. Armen Ph.D.
Co-Founder & Executive Chairman of the Board

Dr. Garo H. Armen Ph.D.
Headquarters

New York, NY
Website

https://www.protagenic.com

FAQs for Protagenic Therapeutics (PTIX)

What is the current share price of Protagenic Therapeutics (PTIX) Today?

The share price of Protagenic Therapeutics (PTIX) is $0.94 (NASDAQ) as of 28-Aug-2026 12:29 EDT. Protagenic Therapeutics (PTIX) has given a return of -20.77% in the last 3 years.

What is the current PB & PE ratio of Protagenic Therapeutics (PTIX)?

Since, TTM earnings of Protagenic Therapeutics (PTIX) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-0.49	-1.05
2024	-0.58	3.14
2023	-0.88	1.20
2022	-0.49	0.25
2021	-5.27	2.40

What is the 52 Week High and Low of Protagenic Therapeutics (PTIX)?

The 52-week high and low of Protagenic Therapeutics (PTIX) are Rs 4.55 and Rs 0.00 as of 29-Aug-2026.

What is the market cap of Protagenic Therapeutics (PTIX)?

Protagenic Therapeutics (PTIX) has a market capitalisation of $ 1 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Protagenic Therapeutics (PTIX)?

Before investing in Protagenic Therapeutics (PTIX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.